logo
BIOA LEGAL DEADLINE: BioAge Labs Investors that Lost Money are Reminded of Pending Class Action – Contact BFA Law by March 10 Court Deadline (NASDAQ:BIOA)

BIOA LEGAL DEADLINE: BioAge Labs Investors that Lost Money are Reminded of Pending Class Action – Contact BFA Law by March 10 Court Deadline (NASDAQ:BIOA)

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for potential violations of the federal securities laws.
If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.
Investors have until March 10, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 11 and 15 of the Securities Act of 1933 on behalf of investors who purchased stock pursuant and/or traceable to BioAge's registration statement for its initial public offering held on or about September 26, 2024. The case is pending in the U.S. District Court for the Northern District of California and is captioned Soto v. BioAge Labs, Inc., et al., No. 25-cv-196.
Why was BioAge Sued under the Federal Securities Laws?
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapeutic products for metabolic diseases, with a primary focus on obesity. The Company's lead product candidate, azelaprag, is an orally available small-molecule agonist of the apelin receptor (APJ), designed to enhance weight loss.
As alleged, BioAge's IPO documents discussed its ongoing STRIDES Phase 2 trial of azelaprag in combination with GLP-1R agonists for enhanced weight loss. BioAge stated that it was collaborating with Eli Lilly and Company ('Lilly') in connection with STRIDES, and that Lilly would be advising and assisting on all aspects of the trial's design and execution. BioAge also stated that it anticipated topline results in Q3 2025 and discussed the potential for a second Phase 2 clinical trial. As alleged, BioAge's statements conveyed to investors that there were no safety concerns and that it expected top line results to meet its primary endpoint goals.
In truth, BioAge was forced to discontinue the STRIDES Phase 2 trial after several subjects exhibited elevated liver enzyme levels, indicating potential organ damage. Consequently, the Company terminated the trial and ceased further enrollment.
The Stock Declines as the Truth is Revealed
On December 6, 2024, BioAge announced that it discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns, after liver transaminitis was observed in subjects receiving azelaprag. The Company stated that the decision to discontinue the STRIDES trial of azelaprag 'became clear' due to 'the emerging safety profile of the current doses tested[.]' This news caused the price of BioAge stock to decline over 76%, from a closing price of $20.09 per share on December 6, 2024, to $4.65 per share on December 9, 2024.
Click here for more information: .
What Can You Do?
If you invested in BioAge you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
Or contact:
212-789-3619
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Congress should think again about foreign investor tax: UK ambassador to US
Congress should think again about foreign investor tax: UK ambassador to US

Yahoo

time11 minutes ago

  • Yahoo

Congress should think again about foreign investor tax: UK ambassador to US

British Ambassador to the U.S. Peter Mandelson is appealing to Congress to think again about the proposed new retaliatory tax on certain foreign investment in the US. 'I think that there's something wrong in principle that you should punish a country's businesses and individuals in America because you don't like what their governments are doing at home,' Mandelson said of Section 899 of the House's 'big, beautiful bill' to implement Trump's agenda. Section 899 would create a retaliatory tax on nationals of countries that impose 'unfair foreign taxes' on American businesses. 'If you've got an argument with their governments, then take it out on the governments. Don't take it out on the businesses and the individuals,' he added. Mandelson also believes that this new foreign investor tax is 'counterproductive' for the United States. 'If you're creating such a risk or potential uncertainty tax on businesses here, then many will think twice about investing further in the United States. I would ask Congress to think again about 899,' he said. According to Mandelson, both Congress and the Trump administration should resolve these matters by negotiation, and 'not by means of a legislative bludgeon', where he says the 'innocent are being punished because it's felt that revenge is due against a country and it's taken out on businesses and individuals here in the US.' He added that Section 899 also sets a 'very difficult precedent,' and it's better resolved by 'government to government negotiation and by discretionary means, not statutory ones.' The provision has stoked concerns on Wall Street over whether foreign investors would pull out of U.S. investments over fears of retribution from Trump. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Musk-Trump Space Showdown Sends Rocket Lab Shares Soaring
Musk-Trump Space Showdown Sends Rocket Lab Shares Soaring

Yahoo

time16 minutes ago

  • Yahoo

Musk-Trump Space Showdown Sends Rocket Lab Shares Soaring

June 9 - Rocket Lab USA Inc (NASDAQ:RKLB) shares climbed about 8% on Monday as investors reacted to a weekend spat between SpaceX CEO Elon Musk and former President Donald Trump. The feud began when Musk criticized Trump's proposed tax legislation on X, prompting Trump to suggest cutting Musk's government contracts. Musk fired back, hinting he might decommission SpaceX's Dragon spacecraft, currently the only U.S. vehicle for ferrying astronauts to the International Space Station, before retracting the comment. Over the weekend, Musk posted that we have got the spaceships, and they do not, implying U.S. reliance on SpaceX. That argument appears to be fueling interest in rival aerospace firms. RKLB, which holds multiple NASA contracts and is viewed as a contender for Trump's $175 billion Golden Dome missile defense initiative, saw its stock hit $31.21 in morning trading. AST SpaceMobile Inc (NASDAQ:ASTS) shares surged about 17% after reports suggested U.S. policymakers may look beyond SpaceX for various space investments. ASTS, a top customer of Blue Origin, inked a November launch deal with Jeff Bezos' company to deploy up to 45 satellites. Both RKLB and ASTS traded on above-average volume, signaling heightened investor focus on alternative space players amid the high-profile Musk-Trump clash. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Are Companies About to Dump Their Bitcoin? The Warning Signs Are Here
Are Companies About to Dump Their Bitcoin? The Warning Signs Are Here

Yahoo

time18 minutes ago

  • Yahoo

Are Companies About to Dump Their Bitcoin? The Warning Signs Are Here

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. The cryptocurrency landscape has witnessed a significant shift as corporations increasingly adopt bitcoin as a treasury asset. While this trend has contributed to bitcoin's recent price surge, it may also be creating new vulnerabilities in the market that warrant careful consideration. Corporate adoption of bitcoin has accelerated notably, with companies following the playbook pioneered by MicroStrategy (NASDAQ:MSTR). According to Bitcoin Treasuries data, 110 publicly listed companies globally now hold bitcoin, representing a substantial institutional commitment to the digital asset. Don't Miss: — no wallets, just price speculation and free paper trading to practice different strategies. Grow your IRA or 401(k) with Crypto – . Standard Chartered's analysis focuses on a refined sample of 61 companies that purchase bitcoin purely as a treasury holding, excluding industry participants like miners, exchanges, and service providers. This subset collectively owned nearly 674,000 bitcoins as of May's end—representing 3.2% of bitcoin's total 21 million coin supply. The numbers tell a compelling story: these 'bitcoin treasuries' have doubled their holdings over just two months, accumulating close to 100,000 additional bitcoins during this period. This buying pressure has been a key factor driving bitcoin to recent all-time highs. However, Standard Chartered's analysis reveals a concerning dynamic that could eventually reverse this supportive trend. Unlike Strategy, which accumulated bitcoin over time at various price points, many newer corporate entrants have purchased at significantly higher average prices. The bank's research suggests that approximately half of the monitored corporate treasuries would find themselves underwater if bitcoin fell below $90,000. This creates a potential domino effect where companies that entered the bitcoin treasury strategy during price peaks could become forced sellers during market downturns. The risk stems from several interconnected factors: Purchase Price Disparities: Most corporate treasuries in Standard Chartered's sample have average purchase prices well above Strategy's cost basis, making them more vulnerable to market volatility. NAV Multiple Justification: Currently, companies holding bitcoin trade at Net Asset Value multiples above 1, justified by market inefficiencies such as regulatory constraints and conservative institutional investment processes. As these barriers diminish over time, the premium valuations may compress. Corporate Pain Thresholds: Unlike dedicated cryptocurrency companies, traditional corporations may have lower tolerance for significant losses on treasury holdings. Standard Chartered estimates that newer entrants likely couldn't withstand a 50% decline from their average purchase price—a threshold that Strategy weathered during the 2022 crypto winter. Trending: New to crypto? on Coinbase. The analysis suggests that if bitcoin drops more than 22% below companies' average purchase prices, forced selling could emerge. This creates a feedback loop where price declines trigger corporate selling, potentially accelerating further declines. This dynamic differs markedly from Strategy's experience in November 2022, when bitcoin halved but the company maintained its position. Several factors may have aided Strategy's resilience: smaller absolute dollar losses at the time, the absence of U.S. spot bitcoin ETFs providing alternative exposure, and the company's fundamental commitment to bitcoin as a long-term strategy. This corporate treasury trend presents both opportunities and risks for the broader bitcoin market: Positive Factors: Corporate adoption provides institutional legitimacy and substantial buying pressure that has supported recent price appreciation. Risk Factors: The concentration of recent purchases at higher price levels creates potential selling pressure during market stress, possibly amplifying volatility. Timing Considerations: As market inefficiencies that currently justify premium valuations are resolved, bitcoin treasuries could shift from price supporters to sources of downside pressure. While corporate bitcoin adoption represents a significant maturation of the cryptocurrency market, investors should recognize that these treasury strategies may behave differently than those of dedicated bitcoin companies during market stress. The sustainability of this trend will likely depend on bitcoin's price stability and these companies' ability to maintain their positions through potential volatility. As Standard Chartered notes, the question isn't whether these companies will face pressure, but rather how much volatility they can withstand before strategic considerations shift. For market participants, understanding these dynamics becomes crucial as corporate treasuries represent an increasingly significant portion of bitcoin's circulating supply. Their behavior during the next major market downturn will provide important insights into the resilience of this newer form of institutional bitcoin adoption. Read Next: A must-have for all crypto enthusiasts: . Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Image: Shutterstock This article Are Companies About to Dump Their Bitcoin? The Warning Signs Are Here originally appeared on

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store